JB Chemicals and Pharmaceuticals is set to launch molnupiravir 200 mg for the Indian market. Marketed under the brand name Molunamax, it will soon be available all across the country in the next month for the treatment of mild Covid-19

In India, the Central Drugs Standard Control Organisation has recently recommended for grant of permission to manufacture and market. Molnupiravir 200 mg capsule for restricted use under an emergency in the country for treatment of patients above the age of 18 years, diagnosed Covid-19 positive, with SpO2 > 93% and those who have a high risk of progression of the disease. The recommended dose for molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for five days, with or without food. Completion of the full five-day treatment course is important to maximize viral clearance and may help in minimizing the transmission of SARS-CoV-2.

Commenting on the launch, Nikhil Chopra, CEO & Whole-time Director mentioned "We are glad to launch molnupiravir for the Indian market. At a time when India is threatened with the possibility of a third wave, the launch of this product will significantly help the country in its fight against Covid-19. We will work closely with the healthcare professionals, government, and medical communities to ensure molnupiravir's availability across the country so that no patient is left behind."